Preliminary Experience with the Use of Recombinant Factor VIIa to Treat Coagulation Disturbances in Pediatric Patients

Abstract

Recombinant factor VIIa can be used to effectively reverse coagulation disturbances in the pediatric patient even when treatment with fresh frozen plasma has failed. Given its therapeutic potential, prospective, randomized trials are warranted.